UK MHRA Issues Q2 2026 Safety Roundup: Recalls Highlight Supply Chain & Labelling Risks

London, United Kingdom — 29 April 2026

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its April 2026 Safety Roundup, identifying critical issues across pharmaceutical manufacturing, supply chain management, and product labelling. The report chronicles three Class 2 or 3 medicine recalls for manufacturing errors and labelling omissions. Amarox Limited initiated a Class 2 recall for a batch of Sertraline 100mg film-coated tablets due to a manufacturing site error. Crescent Pharma Limited followed with a Class 2 recall for Ramipril 10mg capsules, citing similar manufacturing issues. Omega Pharma Ltd issued a Class 3 recall for specific batches of Napralief 250mg Gastro-Resistant Tablets over missing text in the Patient Information Leaflet (PIL) and on carton packaging, underscoring the severity of regulatory oversight failure.

Beyond recalls, the MHRA highlighted ongoing supply chain pressures, sanctioning the interim supply of USA-labelled Sodium Chloride 0.9% solution and Spanish-labelled Methylphenidate hydrochloride modified-release capsules. This measure aims to mitigate potential supply disruptions, yet it introduces challenges in patient communication and labelling compliance. Doncaster Pharma Limited also announced a Class 4 recall for Hiprex 1g tablets due to an error in Braille embossing on outer packaging, demonstrating the broad spectrum of regulatory requirements impacting product integrity.

In a separate but related development, the European Medicines Agency (EMA) recommended the withdrawal of marketing authorisations for levamisole-containing medicines across the EU. This follows a safety review by the Pharmacovigilance Risk Assessment Committee (PRAC), which concluded that the benefits no longer outweigh the risks due to the serious side effect of leukoencephalopathy. While levamisole lacks a UK marketing authorisation, its off-label use for specific conditions in children means this decision could influence future UK clinical guidance and prescribing practices, necessitating a re-evaluation of alternative treatments.

What this means for United Kingdom

UK supplement and pharmaceutical brand owners must immediately review their Quality Management Systems and supplier audit procedures, specifically for contract manufacturing organisations, following these Class 2/3 recalls. The foreign-labelled stock authorisations indicate potential for increased parallel imports; procurement teams should prepare for greater product variant diversity and the associated compliance burden for patient information leaflets. This scenario may allow for extended lead times for specific SKUs due to reformulation needs. Brand margins could tighten due to increased compliance costs and potential product withdrawal expenses following EMA's levamisole decision, requiring manufacturers relying on off-label levamisole to urgently identify and validate alternative active ingredients for nephrotic syndrome treatments. Regulatory teams should prepare for a potential Q3 2026 MHRA push on labelling accuracy and supply chain resilience.

The MHRA also published a factsheet on Respiratory Syncytial Virus (RSV) vaccines, providing guidance for patients and healthcare professionals. This initiative reinforces the agency's focus on public health communication and vaccine safety, setting a precedent for similar educational materials regarding other public health interventions and potentially new supplement categories.

Many leading brands in this category are manufactured in partnership with Supplement Factory.